ArticleJournal of ovarian research2026
Age at menarche and age-adjusted anti-Müllerian hormone level among women of childbearing age in China.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundTrends toward earlier age at menarche, the starting point in women’s reproductive lifespan, have been observed globally. Whether an earlier age at menarche influences Anti-Müllerian hormone (AMH), a clinical indicator of ovarian reserve, remains unclear due to a lack of community-based data. MATERIALS AND
methodsThis nationwide cross-sectional survey was carried out in China’s 15 provinces from May 2019 to April 2021, utilizing a multistage stratified sampling method to ensure sample representativeness and containing a total of 8 278 women aged 21–49 years. Self-reported age at menarche acts as exposure. Participants were categorized as age at menarche < 14 years group (N = 4 022) and age at menarche ≥ 14 years group (N = 4 256). AMH and AMH subgroups act as primary outcomes.
resultsA total of 8 278 participants were enrolled in this study. Mean (SD) age at menarche of the participants was 13.74 (1.58) years. Age at menarche decreased nearly 1 year from 14.31 years in women aged 45–49 to 13.38 years in women aged 21–24. For every one-year increase in age at menarche, AMH increases by 0.04 ng/ml. Compared with women with age at menarche < 14 years, women with age at menarche ≥ 14 years tend to have higher AMH level no matter in Middle AMH Group (OR, 1.28; 95%CI: 1.07–1.54) or in High AMH Group (OR, 1.43; 95%CI: 1.14–1.80) compared with Low AMH group, especially in women aged 25–29 years and 35–39 years. Stratified analysis showed associations between age at menarche and AMH in women with normal BMI group of 18.5–23.9 kg/m2, regular menstrual cycles, menstrual cycle length of 21–34 days, without polycystic ovary syndrome, infertility, or thyroid-stimulating hormone > 4.0 µIU/ml.
conclusionsOur results support the opinion that women with early age at menarche in a community-based population have lower AMH level. Periodic AMH monitoring are necessary in children/adolescents with an early age at menarche. For individuals with early age at menarche, they should consider the optimal timing for childbearing.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.